采用两种方法对新型链阳菌素RP 59500进行体外抗葡萄球菌活性及测试。
In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods.
作者信息
Aldridge K E, Schiro D D, Varner L M
机构信息
Louisiana State University Medical Center, New Orleans 70112.
出版信息
Antimicrob Agents Chemother. 1992 Apr;36(4):854-5. doi: 10.1128/AAC.36.4.854.
Abstract
The in vitro antistaphylococcal activity of RP 59500, a new streptogramin, was comparable to those of vancomycin and teicoplanin against Staphylococcus aureus, and RP 59500 was the most active agent against coagulase-negative staphylococci. All staphylococcal strains were inhibited by 4 micrograms of RP 59500 per ml, including multiply resistant strains. Broth microdilution and agar dilution testing gave comparable results in 97% of the tests with RP 59500.
摘要
新型链阳菌素RP 59500对金黄色葡萄球菌的体外抗葡萄球菌活性与万古霉素和替考拉宁相当，且RP 59500是针对凝固酶阴性葡萄球菌活性最强的药物。所有葡萄球菌菌株均被每毫升4微克的RP 59500抑制，包括多重耐药菌株。在97%的RP 59500测试中，肉汤微量稀释法和琼脂稀释法给出了相当的结果。
相似文献
1
In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods.采用两种方法对新型链阳菌素RP 59500进行体外抗葡萄球菌活性及测试。
Antimicrob Agents Chemother. 1992 Apr;36(4):854-5. doi: 10.1128/AAC.36.4.854.
2
In-vitro activity of RP 59500, a new semisynthetic injectable pristinamycin against staphylococci.新型半合成注射用普那霉素RP 59500对葡萄球菌的体外活性
Zentralbl Bakteriol. 1996 Apr;283(4):497-501. doi: 10.1016/s0934-8840(96)80127-7.
3
In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci.
J Antimicrob Chemother. 1992 Jul;30 Suppl A:15-8. doi: 10.1093/jac/30.suppl_a.15.
4
RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci.RP 59500，一种对北美葡萄球菌近期分离株具有高度活性的新型链阳性菌素。
Diagn Microbiol Infect Dis. 1993 Mar-Apr;16(3):223-6. doi: 10.1016/0732-8893(93)90113-l.
5
Post-antibiotic effect of the new streptogramin RP 59500.新型链阳菌素RP 59500的抗生素后效应
Eur J Clin Microbiol Infect Dis. 1992 Jul;11(7):642-5. doi: 10.1007/BF01961676.
6
In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies.
J Antimicrob Chemother. 1992 Jul;30 Suppl A:59-65. doi: 10.1093/jac/30.suppl_a.59.
7
Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin.德国全国多中心研究：葡萄球菌血流分离株中的抗生素耐药性患病率及奎奴普丁-达福普汀的体外比较活性
J Clin Microbiol. 2000 Aug;38(8):2819-23. doi: 10.1128/JCM.38.8.2819-2823.2000.
8
In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria.
J Antimicrob Chemother. 1992 Jul;30 Suppl A:29-37. doi: 10.1093/jac/30.suppl_a.29.
9
A collaborative study of the in-vitro sensitivity to RP 59500 of bacteria isolated in seven hospitals in France.法国七家医院分离出的细菌对RP 59500的体外敏感性的合作研究。
J Antimicrob Chemother. 1992 Jul;30 Suppl A:53-8. doi: 10.1093/jac/30.suppl_a.53.
10
Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.新型胃肠外注射半合成链阳菌素RP 59500对具有多种对大环内酯-林可酰胺-链阳菌素类抗生素耐药机制的葡萄球菌的活性。
J Antimicrob Chemother. 1992 Jul;30 Suppl A:67-75. doi: 10.1093/jac/30.suppl_a.67.
引用本文的文献
1
Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics.奎奴普丁-达福普汀与万古霉素联合应用对耐甲氧西林金黄色葡萄球菌的体外抗菌活性及在实验性心内膜炎中的疗效，以及与对大环内酯类、林可酰胺类和链阳菌素B型抗生素的交叉耐药性的关系。
Antimicrob Agents Chemother. 2002 Sep;46(9):3061-4. doi: 10.1128/AAC.46.9.3061-3064.2002.
2
Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.奎奴普丁-达福普汀与利福平联合用药在体外以及针对对大环内酯-林可酰胺-链阳菌素抗生素具有不同耐药表型的金黄色葡萄球菌菌株所致实验性心内膜炎中的活性。
Antimicrob Agents Chemother. 2001 Apr;45(4):1244-8. doi: 10.1128/AAC.45.4.1244-1248.2001.
3
Influence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureus.对链阳性菌素A类抗生素的耐药性对奎奴普丁-达福普汀体外活性及对金黄色葡萄球菌所致实验性心内膜炎的影响。
Antimicrob Agents Chemother. 2000 May;44(5):1168-73. doi: 10.1128/AAC.44.5.1168-1173.2000.
4
Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.奎奴普丁/达福普汀：用于治疗严重革兰氏阳性菌感染的综述
Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008.
5
Quinupristin-dalfopristin.奎奴普丁-达福普汀
Drugs. 1996 Sep;52(3):406-15. doi: 10.2165/00003495-199652030-00006.
6
Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.奎奴普丁/达福普汀的抗菌活性。临床应用原理。
Drugs. 1996;51 Suppl 1:31-7. doi: 10.2165/00003495-199600511-00007.
7
Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.革兰氏阳性菌中对抗菌药物的新出现耐药性。肠球菌、葡萄球菌和非肺炎链球菌。
Drugs. 1996;51 Suppl 1:6-12. doi: 10.2165/00003495-199600511-00004.
8
Current perspectives on glycopeptide resistance.糖肽类耐药性的当前观点
Clin Microbiol Rev. 1995 Oct;8(4):585-615. doi: 10.1128/CMR.8.4.585.
9
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.注射用链阳性菌素类抗生素RP59500对耐万古霉素革兰氏阳性菌的体外活性
Antimicrob Agents Chemother. 1993 Mar;37(3):598-601. doi: 10.1128/AAC.37.3.598.
10
In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis.链阳性菌素RP 59500的两种成分在实验性心内膜炎心脏赘生物中的体内活性及渗透情况。
Antimicrob Agents Chemother. 1994 Mar;38(3):432-7. doi: 10.1128/AAC.38.3.432.
本文引用的文献
1
In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.半合成注射用普那霉素RP 59500对葡萄球菌、链球菌和肠球菌的体外活性
Antimicrob Agents Chemother. 1991 Mar;35(3):553-9. doi: 10.1128/AAC.35.3.553.
Zotero 插件